best peptides FAQ

Dihexa or epithalon may address the bottleneck. Caloric restriction activates AMPK and mTOR pathways that signal autophagy, but if lysosomal function is impaired by lipofuscin accumulation or mitochondrial dysfunction, the signal doesn't translate to clearance. Epithalon reduces lipofuscin burden, while Dihexa directly increases autophagic flux via HGF signaling. Pair with mitochondrial support (SS-31 or Cerebrolysin) for optimal effect.

Combine a GLP-1 agonist with an anti-inflammatory peptide like thymosin alpha-1 or KPV 5MG. Chronic low-grade inflammation is both a consequence and a cause of insulin resistance—visceral adipose tissue secretes TNF-alpha, IL-6, and resistin, which directly impair insulin receptor signaling and promote hepatic steatosis. Thymosin alpha-1 modulates T-regulatory cell function and reduces macrophage-derived inflammatory cytokines, while KPV (a tripeptide fragment of alpha-MSH) inhibits NF-kB activation and reduces inflammatory signaling in adipose tissue. This combination addresses both the metabolic dysfunction (via GLP-1 agonism) and the inflammatory milieu that perpetuates insulin resistance even after weight loss.

Combine SS-31 or MOTS-C with an immune-modulating peptide such as thymosin alpha-1 or KPV. SS-31 addresses mitochondrial oxidative damage, while thymosin alpha-1 reduces inflammatory cytokine release that drives maladaptive remodeling. These mechanisms are complementary rather than redundant. Mitochondrial dysfunction and chronic inflammation represent two distinct but interconnected pathways driving heart failure progression. Preclinical models combining mitochondrial and immune-modulating peptides demonstrate additive protective effects that exceed either peptide administered alone.

Store unreconstituted lyophilised peptides at −20°C to maintain long-term stability. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Peptides reconstituted with standard saline degrade within 7 days even under refrigeration. If your protocol extends beyond 28 days, reconstitute smaller aliquots weekly rather than preparing the entire vial at once. Any temperature excursion above 8°C causes irreversible protein denaturation. A single overnight exposure to room temperature can eliminate therapeutic activity entirely, turning the preparation into inactive saline.

Use AMPK-activating peptides like MOTS-C or 5-Amino-1MQ rather than appetite-suppressing GLP-1 agonists. The metabolically obese normal weight (MONW) phenotype—normal BMI with elevated visceral fat and insulin resistance—responds poorly to caloric restriction because the problem isn't total energy intake but impaired mitochondrial glucose oxidation and ectopic fat deposition. MOTS-C enhances skeletal muscle glucose uptake by increasing GLUT4 translocation and mitochondrial respiratory capacity, which improves insulin sensitivity without requiring weight loss. Preclinical evidence shows MOTS-C reversed insulin resistance in lean animals fed high-fat diets, confirming the effect is metabolic rather than weight-dependent.

Neither GLP-1 agonists nor thymic peptides produce acute effects. Both require weeks to reach steady-state impact. AMPK activators like AICAR analogs reduce hepatic gluconeogenesis within hours, making them suitable for same-day glucose challenge protocols. The trade-off: AMPK activation doesn't address long-term insulin sensitivity the way incretin analogs do. For acute studies, use AMPK activators. For chronic metabolic adaptation, use GLP-1 receptor agonists with 4–8 week observation windows.

Administer TB-500 at 2.5mg twice weekly for 4–6 weeks to target the remodeling phase. By week three, the inflammatory phase has ended and proliferative activity (new muscle fiber formation) is tapering. TB-500's anti-fibrotic properties remain relevant because collagen remodeling continues through week 8. BPC-157's angiogenic effects are less critical after vascularization is established, so prioritize TB-500 and consider adding a GH secretagogue like CJC-1295/Ipamorelin to enhance collagen cross-linking during late-stage recovery.

You'll see weight loss, not recomposition. The scale moves but body composition doesn't improve meaningfully. Growth hormone secretagogues mobilise fat and create anabolic potential, but muscle protein synthesis requires mechanical tension from resistance training to activate mTOR signalling pathways. Research comparing peptide use with and without structured training consistently shows that untrained subjects lose fat and muscle proportionally, while trained subjects lose fat while maintaining or gaining lean mass. The peptide creates the hormonal environment; training provides the stimulus that directs where those hormones act.

Add a thymic peptide to the protocol. Inflammatory cytokines (IL-6, TNF-α) activate serine kinases that phosphorylate insulin receptor substrate-1 at inhibitory sites. Blocking downstream glucose uptake even when insulin levels are normal. Thymalin restores immune homeostasis by upregulating T-regulatory cells, which suppress macrophage activation in adipose tissue. The glucose improvement is indirect but measurable: studies show 15–20% fasting glucose reduction within 8–12 weeks when thymic peptides are combined with standard metabolic interventions.

Bone healing follows different timelines than soft tissue. Fractures require 6–12 weeks for callus formation and remodeling. BPC-157 has documented effects on tendon-to-bone healing and ligament repair, but its role in bone mineralization is less clear. TB-500 supports periosteal stem cell differentiation, which contributes to callus formation. Most orthopedic peptide protocols still use BPC-157 + TB-500 during weeks 1–4 post-surgery, but extend the timeline to 8–10 weeks rather than tapering at week three. GHK-Cu is less relevant for bone repair since its primary mechanism targets collagen remodeling in soft tissue, not mineralized matrix.

Peptides accelerate repair, but they don't prevent new microtears if you continue high-impact training at the same volume. Reduce mileage by 40–50% and avoid hard surfaces (concrete, asphalt) during the peptide protocol. The goal is to create a net-positive repair environment where collagen synthesis outpaces tissue damage. Continuing full training load while using peptides wastes the compounds. You're repairing tissue as fast as you're tearing it.

Use both. BPC-157 at 250–500 mcg daily near the fracture site accelerates vascular ingrowth and mineralization at the injury zone. Add a systemic GH secretagogue (MK-677 or ipamorelin) to raise background osteoblast activity across the skeleton, which supports callus formation without relying solely on localized recruitment. The combination consistently outperforms either peptide used alone in research models of delayed fracture union.

Gradual load progression is safe and recommended. Peptides accelerate healing, but tissue strength lags behind pain reduction by 2–4 weeks. Feeling better doesn't mean the tissue is fully repaired. Start with pain-free range of motion exercises (passive leg swings, supine hip flexor stretches) at week 2–3. Progress to resistance training at 30–40% of pre-injury load by week 4, increasing 10% per week as long as pain remains absent. High-intensity plyometrics (sprinting, jumping) should wait until week 8–10 for Grade 2 strains, longer for Grade 3. Continuing peptides during the return-to-training phase supports the final remodeling stage and reduces re-injury risk.

Administer BPC-157 no earlier than day 5 post-surgery to avoid interfering with macrophage activity during debris clearance. The inflammatory phase (days 0–5) is necessary. Your body is removing dead cells and preparing the wound bed for new tissue. Introducing angiogenic peptides too early can theoretically prolong swelling by recruiting blood vessels before the site is ready. TB-500 is considered safer for earlier use since its primary mechanism is cell migration rather than vascular recruitment, but most protocols still wait until day 5 to begin any peptide administration. If you've already started during days 0–4, monitor for prolonged swelling or delayed wound closure and consider pausing until inflammation visibly resolves.

Begin with BPC-157 only. Its angiogenic mechanism works during acute inflammation when VEGF signalling is naturally elevated. Adding TB-500 or GHK-Cu too early can interfere with the inflammatory phase that clears debris and damaged cells. Wait 7–10 days before introducing TB-500, and reserve GHK-Cu for week 3 or later when collagen remodelling begins.

Diminishing returns set in quickly. Combining CJC-1295, Ipamorelin, and MK-677 doesn't triple growth hormone output because all three compounds target the same receptor pathways. Once GH secretion reaches 3–4× baseline (achievable with CJC-1295/Ipamorelin alone), adding more secretagogues produces minimal additional GH release but increases side effect risk, particularly insulin resistance and water retention from chronically elevated GH. The more effective approach stacks compounds from different categories: one GH secretagogue plus one metabolic modulator, allowing independent pathway activation without redundancy.

Growth hormone secretagogues take 14–21 days to produce measurable IGF-1 elevation and metabolic rate changes. The lag reflects the time required for hepatic IGF-1 synthesis and downstream anabolic signaling to establish. If no change occurs by week three, the most common causes are underdosing (effective MK 677 doses start at 12.5mg daily), dosing at inconsistent times (which disrupts pulsatility), or administering peptides that have degraded due to improper storage. Verify refrigeration at 2–8°C for reconstituted peptides and confirm dosing consistency before concluding non-response.

Continue physical therapy while adding peptide support. BPC-157 and TB-500 modulate the inflammatory environment that prevents tissue remodelling, but they don't replace biomechanical correction. Research shows 85% of IT band syndrome cases involve hip abductor weakness or excessive hip adduction during gait, which foam rolling cannot address. Peptides accelerate tissue repair, but if the underlying movement pattern persists, re-injury is inevitable. Combine peptide protocols with targeted hip strengthening (glute medius activation, single-leg stability drills) for sustainable outcomes.

Shift protocol focus to GHK-Cu exclusively during weeks 3–8 to optimize remodeling instead. BPC-157 and TB-500 provide minimal benefit after peak fibroblast activity ends around day 21. Their mechanisms target cell recruitment and migration, which are largely complete by week three. GHK-Cu remains effective throughout the remodeling phase because collagen turnover continues for months. You won't recover the accelerated closure rate that earlier peptide use would have provided, but you can still improve final scar quality and tensile strength. Research shows GHK-Cu administered during weeks 4–12 reduces hypertrophic scarring and improves collagen alignment even when started late.

Reassess injury severity and peptide quality. If pain persists at the same level after three weeks, the strain may be more severe than initially assessed. Grade 2 or Grade 3 tears require imaging (MRI or ultrasound) to rule out complete rupture. Verify peptide source and storage: degraded BPC-157 loses activity but looks identical to fresh product. Switch to a verified supplier with third-party HPLC purity testing. Consider adding TB-500 to the protocol if you've been using BPC-157 alone. Some injuries respond better to combined angiogenesis and matrix remodeling than to angiogenesis alone.